WO2018012773A1

WO2018012773A1 - Anti-inflammatory composition containing uldavioside a compound

Info

Publication number: WO2018012773A1
Application number: PCT/KR2017/006932
Authority: WO
Inventors: 서원호; 김익휘; 차병윤; 김호
Original assignee: 주식회사 엘큐바이오
Priority date: 2016-07-12
Filing date: 2017-06-30
Publication date: 2018-01-18
Also published as: KR20180007088A; KR101831438B1

Abstract

The present invention relates to an anti-inflammatory composition containing as an active ingredient an uldavioside A compound separated from an Ulmus davidiana Planch. extract. More particularly, the uldavioside A compound shows an anti-inflammatory activity by means of inhibiting expression of inflammation-related factors and inflammatory cytokine and thus can be utilized as a composition for preventing or treating inflammatory diseases and a functional health food for remedying inflammatory diseases.

Description

Specification

Name of Invention: Anti-inflammatory Compositions Containing Adavioside A Compound

[1] The present invention is Ulda bioseed isolated from the extract of Ulm davidiana Planch.

It relates to anti-inflammatory composition containing A (Uldavioside A) compound as an active ingredient.

Background

[2] Inflammation is a hostess against wounds, microbial infections, etc.

Although important for pathological mechanisms following defensive mechanisms, persistent and excessive inflammatory reactions can lead to tissue damage that can lead to a variety of diseases, including rhinitis, bronchitis, hepatitis, and arthritis. In the case of severe degenerative diseases, research reports show that the pathophysiology is closely related to the inflammatory immune response, and interest in the mechanism and role of inflammatory reactions is rapidly increasing. It is increasing.

[3] Macrophages are the most representative immune cells that control inflammatory reactions. Activated macrophages are tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6), progetaglandin E2 (PGE ₂ ) and NO. secrete a variety of inflammation-related factors, such as nitric oxide and reactive oxygen species (Laskin, DL, et al, 2011). On the other hand, overexpression of these inflammation-related factors is associated with rheumatoid arthritis, osteoporosis, sepsis, and vascular disease. ， Cancer light

Induction (Lawrence, T., et al., 2002).

[4] Ubnus davidiana Planch is a dried bark and root bark of the cork layer of the locust tree (t // mj «davidiana var. Japonica Nakai), belonging to the ulmaceae family. Toxic, swelling, arthritis, gastric ulcer, gastrointestinal disease, etc., has been reported to have an excellent effect on expectorants, anticancer, wound healing drugs and inflammation (Duke JA, 1985).

β-sitosterol, phytosterol, stimasterol, tannin, starch, polysaccharide, etc.

Friedelin, a component of pain relief,

Separation of epipreenderalol (epifriendelalol), taraxerol (taraxerol) (Matsuzaki T., et al, 1985) and chemical composition studies (Duke JA, 1985), but the various physiological activities of the root skin Attempts have not been made to date.

[5] In the present study, the inventor completed the present invention by confirming that the Uldabiosad A compound isolated from the root extract has excellent anti-inflammatory activity during the study of the anti-inflammatory composition containing the extract of root skin. Could. [6] As a prior art, Korean Patent Laid-Open Publication No. 2000-0041190 describes prevention and treatment of diseases such as inflammation and wounds of a pharmaceutical composition including milk white skin, and Korean Patent Laid-Open Publication No. 2006-0078305 describes It is interesting to have a cosmetic composition that has an anti-inflammatory effect, which contains herbal extracts.

The composition of the present invention is different because no Uldabioside A compound is listed.

[7] Also, as a non-patent document, Son B.W., et al.

Compound A: Yes, but no anti-inflammatory effect.

Detailed description of the invention

Other challenges

[8] Bon ^: The object of the invention was to isolate from the extract of Ulmus davidiana Planch

It is to provide an anti-inflammatory composition containing ^' Uldavioside A' as an active ingredient. ^:

Task solution

[9] The present invention provides a compound of Ulvidioside A of Formula 1

It is about the anti-inflammatory composition containing as an active ingredient.

[10] [Formula 1]

[12] The anti-inflammatory composition may be a pharmaceutical composition for the prevention or treatment of inflammatory diseases including a pharmaceutically acceptable carrier.

[13] The inflammatory diseases include inflammatory growth diseases, atherosclerosis, inflammatory collagen vascular diseases, glomerulonephritis, bedsores, ^' inflammatory skin diseases, sarcoidosis, retinitis, gastritis, hepatitis, enteritis, arthritis, tonsillitis, pharyngitis, bronchitis, pneumonia, It can be selected from the group consisting of pancreatitis, sepsis, degenerative chronic inflammatory disease and nephritis.

[14] The pharmaceutical composition is based on the total weight of the composition of

May be contained in 001 to 50% by weight.

The composition may be a pharmaceutical composition formulated as an oral administration agent, a spraying agent, a gel, an ointment, a cream, or an external preparation.

[16] In addition, the anti-inflammatory composition may be used as a food additive acceptable food.

It may be a dietary supplement for the improvement of inflammatory diseases, including. [17] The inflammatory diseases include inflammatory growth diseases, atherosclerosis, inflammatory collagen vascular diseases, glomerulonephritis, pressure sores, inflammatory skin diseases, sarcoidosis, retinitis gastritis, hepatitis, enteritis, arthritis, tonsillitis, pharyngitis, bronchitis, pneumonia, pancreatitis, It can be selected from the group consisting of sepsis, degenerative chronic inflammatory disease and nephritis.

[18] The dietary supplement is based on the total weight of the composition of Ulda bioseed A compound.

0.001-50% by weight may be contained.

The dietary supplement may be a dietary supplement formulated into tablets, capsules, pills, and liquids.

[20] Ahabon's invention is explained in detail.

The present invention relates to an anti-inflammatory composition containing the uldabioside A compound of Formula 1 as an active ingredient.

The compound of Chemical Formula 1 can be synthesized according to a conventional method, can be prepared as a pharmaceutically acceptable salt, or can be separated and purified from the dermis extract.

[25] The root bark is a dried bark and root bark of the bark of the bark (W / "davidiana var. Japonica Nakai) belonging to the ulaceae family.

[26] The roots extract of the roots is water, lower alcohols of C1 to C4 or their

The mixed solution can be extracted as a solvent. The C1 to C4 alcohols can be selected from the group consisting of methanol, propanol, isopropanol, butanol and isobutanol.

[27] The compound separated from the root skin extract can be purified using column chromatography. Addition chromatography can include silica gel column chromatography, HP-20 column chromatography, and HP-20 column chromatography.

chromatography, RP-18 column chromatography, LH-20 column chromatography, and high-performance liquid chromatography.

[28] The anti-inflammatory composition may be used for inflammatory diseases, including pharmaceutically acceptable carriers. It may be a prophylactic or therapeutic pharmaceutical composition.

[29] The inflammatory disease is a disease caused by inflammation of the main lesion, inflammatory growth disease,

Atherosclerosis, inflammatory collagen vascular disease, glomerulonephritis, pressure sores, inflammatory skin disease, sarcoidosis, retinitis, stomach, hepatitis, hepatitis, arthritis, tonsillitis, pharyngitis, bronchitis, pneumonia, pancreatitis, sepsis, degenerative chronic inflammation In the group consisting of: can be selected.

[30] Inflammatory growth disease is a disease that causes chronic inflammation alone, and may be ischemic growth disease, Crohn's disease, and intestinal diverticulum.

[31] The pharmaceutical composition may contain 0.001 to 50% by weight, preferably 0.001 to 40% by weight, based on the total weight of the composition of davioside A compound.

It may be contained in 0.001-30% by weight.

[32] The pharmaceutical compositions are oral formulations, external preparations, suppositories, and sterile injections of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, sprays, etc., in accordance with conventional methods. Carriers, excipients, and diluents that may be included in the pharmaceutical composition may include lactose, textose, sucrose, solbi, manny, xili, erysme, malty, starch, Acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate,

Propyl hydroxybenzoate, talc, hemp; nem stearate, and mineral oil. For the preparation, diluents or excipients such as layering agents, bulking agents, binders, wetting agents, disintegrating systems, surfactants, etc. are used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which may be used in the compounds of the invention of Uldabioside A; at least one excipient, for example, Prepared by mixing starch, calcium carbonate, sucrose or lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid oral agents for oral use include suspensions, solvents, emulsions, and syrups, and various excipients besides the commonly used simple diluents, liquid paraffin, etc. For example, wetting agents may include sweeteners, fragrances, preservatives, etc. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-drying agents, suppositories. Vegetable oils such as propylene glycol, polyethylene glycol, olive oil, and injectable esters such as ethyl oleate may be used. Examples of suppositories include witepsol, macrogol,

Tween-61, cacao butter, laurin, glycerogelatin and the like can be used.

The pharmaceutical composition may be, but is not limited to, a pharmaceutical composition formulated as an oral dosage form, a spray, a gel, an ointment, a cream, or an external preparation.

[34] The dosage of the pharmaceutical composition of the present invention will vary depending on the age, sex, weight of the subject to be treated, the severity of the particular disease or disease to be treated, the severity of the disease or pathology, the route of administration and the prescriber's judgment. Dose determination based on It is within the level of those skilled in the art, and generally the dosage is about 0.01 mg / kg / day

It is in the range of 2000 mg / kg / day. The preferred dosage is lmg / kg / day to 500 mg / kg / day. Dosing can be given once a day or multiple times. The above doses do not limit the scope of the present invention in any way.

[35] The pharmaceutical composition of the present invention has various pathways in mammals such as rats, cattle, and humans.

All modes of administration can be anticipated, e.g., by oral, rectal or intravenous, muscular, subcutaneous, endometrial or cerebral vascular injections and skin application: The compounds of the present invention are toxic. It is a drug that can be used safely and for long-term use for the purpose of prevention because there is almost no side effect.

In addition, the anti-inflammatory composition may be a food additive acceptable food additive.

It may be a dietary supplement for the improvement of inflammatory diseases, including.

[37] The dietary supplement is Uldabio: Seed A compound is added to the total dietary supplement weight.

0.001 to 50% by weight, preferably 0.001 to 30% by weight, more preferably

It may be contained in 0.001 to 10% by weight.

[38] The health functional food may be in the form of tablets, capsules, pills, or liquids, and to which the Uldabioside A compound of the present invention may be added, for example, various foods, beverages, Chewing gum, tea, vitamin complexes, and health functional foods.

Effects of the Invention

[39] The present invention relates to a composition for the prophylaxis or treatment of inflammatory diseases, which contains the extract of Jlmus davidiana Planch (Uldavioside A) as an active ingredient. Dichroism

It suppressed the expression of cytokines and confirmed that it has a therapeutic effect on inflammatory skin diseases.

[40] Through Ar, the Uldabioside A Compound of the Invention is Allergic and Inflammatory

Intestinal disease, atherosclerosis, inflammatory collagen vascular disease, glomerulonephritis, inflammatory skin disease, sarcoidosis, retinitis, gastritis, hepatitis, enteritis, arthritis, tonsillitis, pharyngitis, bronchitis, pneumonia, pancreatitis, sepsis, bedsores, degenerative chronic inflammation disease It is expected to be easily used as a therapeutic or health food for various inflammatory diseases such as nephritis. Brief description of the drawings

1 is a cross-sectional view of an Ulviobioside A compound of the present invention.

Is an illustration showing a COSY (bold lines) and HMBC correlation between C ¾- ¹³ (arrow).

2 shows Raw 267.4 (A), C 2 C 12 (B) and

Cytotoxicity results in NIH3T3 (C) cells.

3 shows Raw264 / 7, C2C12, and the treatment according to the treatment of Uldabioside A compound of the present invention.

The expression levels of TNF-a (A), IL-1 (B) and NO (C), which are inflammation-related factors in NIH3T3 cells, are shown.

4 shows the treatment of uldabioside A compound with the present invention in inflammatory reaction caused by hypoxia. The iNOS (A) and ICAM-1, MMP-2 and MMP-9 (B) expressions are shown.

FIG. 5 shows the results of treating the bed sores with creams containing dabioside A compound of the present invention. (A) Treatment of bed sores after treatment for 14 days in 4 patients with antibiotic resistance or bed sores. (B) shows the result of 30 days treatment for 4 patients with pressure sores that started to appear fascia, and (C) showed treatment effect for 4 days with 4 patients with pressure sores that had begun fascia.

Best mode for carrying out the invention;

Hereinafter, preferred embodiments of the present invention will be described in detail. However, the present invention is not limited to the embodiments described herein but may be embodied in other forms.

Rather, the information presented here is intended to be thorough and complete, and to provide those skilled in the art with a full understanding of the present invention.

Example 1 Separation of Uldabioside A Compound

[48] The root skin (fZ / m davidiana Planch) was purchased from a farm and used. After adding purified water 1 to 10 g of dried rooted skin, use a semi-continuous low temperature vacuum extractor.

Repeated treatment for 12 hours at 25 ° C. was repeated three times, and the root extract was extracted using filter paper to remove the impurities, and the root extract was obtained. 30% methanol, 50% methane and 70% methanol were obtained. HP-20 column with solvent elution conditions, increasing polarity in order of 100% methanol

Chromatography (Diaion HP-20 column chromatography) afforded three fractions (Fr. E-1-E-3). Double Fr. Uldabioside A compound (9 mg) was isolated by performing Sephadex LH-20 column chromatography using E-1 as 70% methane using isocratic solvent.

Example 2 Physical and Chemical Structure Identification of Uldabioside A Compound

[5 is Uldavioside A;

[51] light brown powder;

[52] NMR and ¹³ C NMR data, see Table 1 below;

[53] ESI-MS [M + H] ⁺ m / z 423.1, C ₂₀ H ₂₂ O ₁₀ .

[54] [Table 1]

R (150 MHz in CD ₃ OD) spectroscopy data

H NMR (600 MHz in CD ₃ OD) spectroscopy data

Experimental Example 1 Culture of Animal Cells

[56] A macrophage host to confirm the activity of the Uldabioside A compound of the present invention.

Raw264.7 cells, myoblast C2C12 cells, fibroblast NIH3T3 cells with 10% FBS (fetal bovine serum), 100 U / ^ penicillin and 100 _// g / m £ Dulbecco's Modified Eagle's Medium (DMEM) medium containing streptomycin was added and cultured in a 3 ⁷ ° C, 5% C0 ₂ incubator.

Experimental Example 2: Confirmation of Cytotoxicity of Uldabioside A Compound

[58] Cytotoxicity by Uldabioside A Compound of the Invention

MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) assay method was used.

[59] ⁴ 8 wells of Raw264.7, C2C12 and NIH3T3 cells cultured in Experimental Example 1

Plates were aliquoted with ⁵ cells of IxlO per well and cultured for 24 hours, followed by 18 hours of DMEM medium containing 0.5% FBS, IOOU / I penicillin and 10 «g / ni £ streptomycin. . After 18 hours of culture, the Uldabioside A compound was treated with ΙμΜ and 10μΜ and incubated for 24 hours. Raw264.7, C2C12 and NIH3T3 cells without any treatment were used as controls. After 24 hours, the cells were treated with MTT solution at a concentration of 100 / g / m and reacted at 37 ° C for 3 hours, and then the culture solution was removed and the formed formazan precipitate was removed.

It was dissolved in dimethyl sulfoxide (DMSO) and the absorbance was measured at 570 nm, and the result is shown in FIG.

[26] Raw264.7 (2A) treated with Uldabioside A compound, as shown in FIG.

The survival rate of C2C12 (2B) and NIH3T3 (2C) cells was increased compared to the control group which did not process anything. ：

[61] This suggests that dabioside A compound of the present invention does not exhibit cytotoxicity. ：

Experimental Example 3 Confirmation of Inflammation-Related Factors of Uldabioside A Compound

[63] Inflammation-related factors NO (nitric oxide), TNF-a (tumor necrosis factor-a), and the anti-inflammatory effects of the treatment of the Uldabioside A compound of the present invention.

Expression of IL-1 (3) (interleukin-1 (3)) was immediately determined using the corresponding enzyme-linked immunosorbent assay (ELISA) kit.

[64] 48 wells of Raw264.7, C2C12 and NIH3T3 cells cultured in Experimental Example 1

Incubate for 24 hours by dispensing ⁵ x lxlO cells per well in the plate: After complete removal of medium, DMEM medium containing 0.5% FBS (containing 100 U / m £ penicillin and 100 ^ g / me streptomycin) ) And incubated for 18 hours. After 18 hours of incubation, the Uldabioside A compound was treated with cells to be ΙμΜ and ΙΟμΜ, and then agitated for 1 hour, followed by 2 // g / m of LPS (lipopolysaccharide) and incubated for 24 hours. Raw264, C2C12 and NIH3T3 cells were used as controls. :

[65] Expression of NO, TNF-α, and IL-Ιβ secreted in cell cultures was determined by ELISA:

Measurement was carried out using a kit (ENZO, USA). At this time, the test method was based on the test method provided in the kit, and the results are shown in FIG. 3.

As shown in FIG. 3, the induction of TNF-a (3A), IL-1 (3 (3B) and NO (3C), which are inflammation related factors that were increased by LPS treatment in all Raw264.7, C2C12 and NIH3T3 cells. It was confirmed that the present amount was reduced depending on the treatment concentration of Uldabioside A compound of the present invention.

[68] It was found that the Uldabioside A compound of the present invention exhibited anti-inflammatory activity by inhibiting the expression of inflammation-related factors.

Experimental Example 4 Identification of Inflammatory Anti-Inflammatory Activity of Ulda Bioside A Compound by Low Oxygen

[69] Hypoxia can occur when a smooth blood flow does not occur due to a blockage of peripheral blood vessels, which causes not only cell death but also inflammation. Thus, the Uldabioside A compound of the present invention is caused by hypoxia. Inflammation-related factors, iNOS (inducible nitric oxide synthase), ICAM-1 (intercellular adhesion molecule 1) and inflammatory proteins known as inflammatory proteins The expression levels of matrix metalloproteinase-2 (MMP-2) and MMP-9, which are used as markers, were analyzed.

C70C12 and NIH3T3 cells cultured in Experimental Example 1 were dispensed in a 100cm plate to be 80% full and cultured overnight, and then treated with cells such that Uldabioside A compound became ΙΟμΜ and 20μΜ for 1 hour. After incubation, the cells were incubated for 24 hours in a hypoxic solution (1 ₁ ) 0 & chamber with 94% hydrogen, 5% carbon dioxide, and 1% oxygen to induce hypoxia, at which time no cells were treated. Cells that induced hypoxia and were not treated with the Uldabioside A compound of the present invention were used as negative controls. After 24 hours, the protein was recovered from each cell and the protein expression was confirmed by using the antibodies corresponding to iNOS, ICAM-1, MMP-2 and MMP-9 by Western blot method, and the results are shown in FIG. .

[71] As shown in the expression results of iNOS, an inflammation-related factor in Fig. 4 (A), iNOS expression increased in hypoxia-induced myocytes, whereas

When treated with Uldabioside A, it was confirmed that iNOS expression by hypoxia was suppressed in a concentration-dependent manner.

In addition, as shown in the results of expression of inflammatory proteins ICAM-1 and inflammation-associated biomarkers MMP-2 and MMP-9 in FIG. 4 (B), ICAM- in fibroblasts induced by hypoxia-induced inflammation. 1, While expression of MMP-2 and MMP-9 increased, it was confirmed that the expression of ICAM-1, MMP-2 and MMP-9 was suppressed in the case of treatment with Uldabioside A of the present invention.

[73] Through this, the Uldabioside A compound of the present invention is related to oxygen-induced inflammation.

The treatment effect of the disease was found.

[74] <Experimental Example 5 Determination of the Somatic Treatment Effect of Uldabioside A Compound>

[75] Bed sores are pressured by constant or repetitive pressure in any part of the body.

When the blood is not circulated to the tissue, the tissue is dying, and when the blood flow decreases, inflammation, necrosis, etc. occur in the tissue, and tissue loss occurs. Accordingly, the effect of bed sore treatment by the Uldavioside A compound of the present invention was confirmed.

[76] After washing beds and surrounding tissues with saline solution for 10 patients with 4 bedsores, apply cream containing 0.025% by weight of Uldabioside A compound of the present invention to the surface of bedsores 2 Car cover dressing was performed to protect the sores: The stomach was treated with a cream containing the Ulda Bioseed A compound of the present invention in a two-day cycle, and the degree of recovery of the bedsores was observed. The results are shown in FIG.

[77] As shown in Fig. 5, in the case of 4 patients with antibiotic resistance or emergent bedsores (5A), the bedsores were reduced after 14 days of cream treatment.

In addition, for four patients with pressure sores (5B and 5C) that started to appear fascia, At the time of treatment (5B) at 30 days or at time (5C) at 45 days after treatment, the growth of the granulation tissue was observed to decrease the bed sore area.

[78] In this way, the Uldabioside A compound of the present invention was used to suppress the pressure sores

It can be seen that it can be treated.

[79] <Preparation Example 1.Pharmaceutical preparation>

[80] Formulation Example 1-1 Gel Preparation Pharmaceutical Formulation

[81] 15 wt ^< ¾ of Pluronic F-127 (manufactured by BASF Co.) was added to the preparation container in a 6.0 buffer solution, and then stirred slowly for 20 hours at 4 ° C to obtain a clear viscous liquid. . In a separate container, add 0.025% by weight of the Uldabioside A compound of the present invention in a pH 6.0 complete solution, and then stir, inject it into ¾ the following preparation container and stir. In another separate container, 4% by weight of ethanol and paraoxy 0.1% by weight of benzoic acid methyl ester and 0.1% by weight of paraoxyan; 0.1% by weight of propyl acid propyl ester were added, stirred and dissolved, and then added to the preparation container. The injected mixture was stirred for 20 minutes and then in the refrigerator for 4-5 hours. The yellowish viscous liquid was obtained by leaving it to stand. From the obtained viscous liquid, it heated slowly until a gel was obtained.

[82] Formulation Example 1-2. Ointment-type pharmaceutical preparation

[83] tank: white petrolatum 15 wt% cetostearyl alcohol 10 wt%

7% by weight of hard fluid paraffin and 1.5% by weight of cetomacrogol were heated to about 65 ⁰ C and melted. The molten solution was filtered through 100 μl sieve. Pour purified water into a separate container and 0.025 weight of Uldabioside A compound of the present invention. After stirring and dissolving, the solution was added to a preparation container. In another separate container, 0.12% by weight of paraoxybenzoic acid methyl ester and 0.08% by weight of paraoxybenzoic acid propyl ester were dissolved in a boiling water of 95 ⁰ C. After stirring, the solution was stirred for about 20 minutes, and then emulsified with a homogenizer at a speed of 2500 rpm for about 20 minutes.

Formulation Example 1-3 Preparation of Tablet

200 g of the Uldabioside A compound of the present invention was mixed with 175.9 g of lactose, 180 g of potato starch, and 32 g of colloidal silicic acid. After adding 10% gelatin solution to the mixture, the mixture was ground and passed through a 14 mesh body. The mixture was dried and purified from the mixture obtained by adding 160 g of potato starch, 50 g of active and 5 g of magnesium stearate _.

Formulation Example 1-4 Preparation of Injection Solution

[87] The uldabioside A compound of the present invention, lg, 0.6 g of sodium chloride and 0.3 g of ascorbic acid were dissolved in distilled water to make 100 ^. The solution was added to the bottle and heated at 20 ° C. for 30 minutes to sterilize.

[88] <Production Example 1, Health Food Manufacturing>

[89] Preparation Example 2-1. Manufacture of Health Foods

[9] Uldabioside A Compound of the Invention 200 mg, Vitamin A Combination Amount (Vitamin A Acetate 70, Vitamin E l.Omg, Vitamin B1 0.13 rag, Vitamin B2 0.15 mg, Vitamin B6 0.5 mg, Vitamin B12 0.2 / g, Vitamin C 10 mg, Biotin lO ^ g, Nicotinamide 1.7 mg, Folic acid 50 // g, Pantothenate 0.5 mg) and mineral mixture (ferrous iron sulfate 1.75 mg, zinc oxide 0.82 mg, magnesium carbonate 25.3 mg, potassium monophosphate 15 mg, crab calcium phosphate 55 mg, potassium citrate 90 mg, calcium carbonate 100 mg, magnesium chloride) 24.8 rag) was prepared, and granules were prepared and health foods were prepared according to the conventional method.

[91] Second Example 2-2. Manufacture of Healthy Beverages

[92] Uldabioside of the present invention: 1.28 mg of A compound, 522 mg of honey, 5 rag of thioctoamide amide, 10 mg of nicotinic acid amide, 3 rag of sodium riboflavin hydrochloride, 2 mg of pyridoxine hydrochloride, 30 rag of inosine, ortho acid _: 50 mg, and water 200i. And the contents were prepared using the conventional method.

Claims

Claims [1] An anti-inflammatory composition characterized in that it contains an uldavioside A compound of formula 1 as an active ingredient.

[Formula 1]

[Claim 2] In paragraph 1,

The anti-inflammatory composition is an anti-inflammatory composition characterized in that the pharmaceutical composition for the prevention or treatment of inflammatory diseases, including a pharmaceutically acceptable carrier. ：

[Claim 3] In paragraph 2,

The inflammatory diseases include inflammatory growth diseases, atherosclerosis, inflammatory collagen vascular disease, glomerulonephritis, pressure sores, inflammatory skin diseases, sarcoidosis, retinitis, gastritis, hepatitis, enteritis, arthritis, tonsillitis, pharyngitis, bronchitis, pneumonia, pancreatitis, sepsis, Anti-inflammatory composition characterized by being selected from the group consisting of degenerative chronic inflammatory diseases and nephritis.

[Claim 4] In paragraph 2,

The pharmaceutical composition is an anti-inflammatory composition characterized in that the Uldavioside A compound is contained in an amount of 0.001 to 50% by weight based on the total weight of the composition.

[Claim 5] In any of paragraphs 2 to 4,

The composition is an anti-inflammatory composition characterized in that the pharmaceutical composition formulated with oral administration, sprays, gels, ointments, creams or external preparations.

[Claim 6] In paragraph 1,

The anti-inflammatory composition is characterized in that it is a dietary supplement for the improvement of inflammatory diseases, including a crop additive acceptable in food science.

[Claim 7] In paragraph 6,

The inflammatory diseases include inflammatory growth diseases, atherosclerosis, inflammatory collagen vascular disease, glomerulonephritis, pressure sores, inflammatory skin diseases, sarcoidosis, retinitis, gastritis, hepatitis, enteritis, arthritis, tonsillitis, pharyngitis, bronchitis, pneumonia, pancreatitis, sepsis, Degenerative Anti-inflammatory composition characterized by being selected from the group consisting of chronic inflammatory diseases and nephritis.

[Claim 8] In paragraph 6,

The dietary supplement is formulated with respect to the total weight of the composition

Anti-inflammatory composition characterized by being contained in 0.001-50% by weight.

[Claim 9] In paragraph 6,

The health functional food is an anti-inflammatory composition, characterized in that formulated as tablets, capsules, pills and liquids.